Evaxion Expands AI-Immunology Platform Into Autoimmune Diseases With Two Novel Treatment Concepts
核心洞察
Evaxion has begun applying its AI-Immunology (搜索) platform to autoimmune diseases (搜索), expanding its therapeutic focus beyond cancer and infectious diseases and marking a 2026 company milestone.
The company is experimentally testing a tolerogenic vaccine (搜索) concept and an autoantibody binder (搜索) concept, both designed to target underlying disease pathology rather than symptoms alone.
Initial experimental data from the ongoing studies will be presented at the Protein & Antibody Engineering Summit (PEGS) Europe in Lisbon, Portugal, on November 18, 2026.
Evaxion A/S (搜索) (NASDAQ: EVAX) has begun applying its AI-Immunology (搜索)™ platform to autoimmune diseases (搜索), expanding the clinical-stage TechBio company's therapeutic focus and marking another company milestone for 2026. The Copenhagen-based company announced on September 14, 2026, that it is now conducting experimental testing of two novel AI-Immunology™-based treatment concepts in the autoimmune space.
According to the company, both concepts could potentially offer higher efficacy and fewer side effects than currently available treatments, based on what it describes as AI-Immunology (搜索)™'s unique capabilities in addressing underlying disease pathologies with very high specificity. Evaxion frames the move as a response to an area of high unmet need, noting that most current autoimmune disease treatments address only symptoms, with few approaches focused on the underlying disease.
"We are very excited to apply AI-Immunology (搜索)™ in a new disease area and validate these novel concepts, which could potentially target underlying disease biology rather than just symptoms," said Birgitte Rønø, CSO and COO of Evaxion. "Autoimmune diseases (搜索) can be severely debilitating and even lethal placing a massive burden on patients, relatives and society. With AI-Immunology™ we have unique opportunities to potentially improve treatment options in this area."
Two Distinct Therapeutic Concepts Under Investigation
Evaxion is testing a tolerogenic vaccine (搜索) concept and an autoantibody binder (搜索) concept. The tolerogenic approach involves vaccination with T-cell epitopes (搜索) alongside co-delivery of immune modulators that direct the immune system toward tolerance; the company states that AI-Immunology (搜索)™ has unique capabilities in finding and prioritizing the best epitopes for this purpose.
The autoantibody binder (搜索) concept uses an antigen construct designed to capture autoantibodies (搜索), which Evaxion describes as the main pathogenic drivers in many autoimmune diseases (搜索). According to the company, autoantibodies bind to normal tissue, causing tissue damage and/or blocking of key physiological functions, so clearing these autoantibodies is expected to treat the diseases.
Data from the ongoing experiments will be presented at the Protein & Antibody Engineering Summit (PEGS) Europe, taking place in Lisbon, Portugal, on November 18, 2026.
Platform Scope and Partnership Potential
Evaxion describes AI-Immunology (搜索)™ as enabling the development of several novel therapeutic concepts focused on disease modification. The company characterizes autoimmune diseases (搜索) as offering significant partnership potential across all stages of drug development.
AI-Immunology (搜索)™ is Evaxion's proprietary, clinically validated and scalable artificial intelligence platform, which the company says harnesses AI to decode the human immune system and develop novel drug candidates. Evaxion reports that the platform supports rapid, efficient and high-quality target discovery, drug design and development, with a team of more than 40 experts covering the value chain from target discovery to clinical development.
The company's existing clinical pipeline comprises both personalized and off-the-shelf cancer vaccine candidates and prophylactic vaccine candidates for infectious diseases, all of which Evaxion states address high unmet medical needs. The autoimmune program represents a new disease area for the platform, which had previously been applied to cancer and infectious diseases.